This device has been enhanced, leading to a most recent FDA approval in June 2015 of the thirdgeneration balloon-expandable valve (3) . In January 2014, the FDA also approved a self-expanding prosthesis (CoreValve, Medtronic, Dublin, Ireland) for TAVR on the basis of nonrandomized data in patients who were at prohibitive surgical risk (4).
The mortality and quality-of-life benefits of TAVR have led it to become a widely adopted therapy for patients with SAS who are at prohibitive and high surgical risk. Within the first 19 months post-approval, nearly 8,000 patients underwent TAVR (5) . Estimates project >100,000 TAVR candidates in North America with >9,000 annual incident possible procedures (6).
However, TAVR is an expensive technology, and treating all eligible North American patients with TAVR would cost >$7 billion (7). Given these potentially large expenses, cost-effectiveness analyses are important to put the procedure in perspective compared with alternative strategies. On the basis of randomized data, TAVR in high surgical-risk patients with the balloon-expandable valve was found to be cost-effective only via the iliofemoral, but not the transapical, route (8) . In the overall population, the incremental cost-effectiveness ratio (ICER) was $76,877 per quality-adjusted life year (QALY) gained (8) . There are no cost-effectiveness analyses of the self-expanding prosthesis, but its studies have enrolled a slightly different patient population.
In this issue of the Journal, Reynolds et al. (9) present a rigorous economic analysis using data from the U.S. CoreValve High Risk Study, which randomized 795 patients (mean age 83 years, 53% male) with SAS and New York Heart Association functional class II or greater heart failure symptoms at increased surgical risk to TAVR or SAVR (10) . TAVR patients had lower 2-year mortality (11) . Although both TAVR and SAVR improved disease-specific and generic health status at 1 month, only patients receiving iliofemoral TAVR had a significant health status benefit over SAVR (12) . This relative improvement was not sustained at 6 or 12 months. A relative benefit isolated to iliofemoral patients is consistent with findings from highrisk patients treated with the balloon-expandable valve (13) . This may be due to delayed recovery through Yale University, to develop methods and facilitate best practices for medical device surveillance; and chairs a cardiac scientific advisory board for United Healthcare. Dr. Dhruva has reported that he has no relationships relevant to the contents of this paper to disclose. Neil Moat, MBBS, served as Guest Editor for this paper. (19, 20) . Also, the >$100 million that was spent monthly on ezetimibe before any outcomes trials provided evidence of its clinical benefit indicates that our health care system can sometimes pour resources into uncertain therapies (21) . Even with new treatments lacking outcomes data, we similarly seem im- given the mortality and quality-of-life benefits of TAVR, and although we do not need to fixate on achieving the $50,000/QALY, we must monitor costeffectiveness over time as science moves forward.
These analyses are likely to become increasingly important as cost-consciousness takes a greater hold in health care, and as a society, we will achieve greater benefit if we can curb misuse and direct our resources toward beneficial interventions. In deciding what not to do based on cost, we should start where effectiveness is unproven.
